Tykerb (chemical name: lapatinib) has been approved by the U.S. Food and Drug Administration (FDA):
- to be given in combination with Xeloda (chemical name: capecitabine), a type of chemotherapy, to treat advanced-stage, HER2-positive breast cancer that has stopped responding to anthracyclines, taxanes, and Herceptin.
- to be given in combination with Femara (chemical name: letrozole), a type of hormonal therapy, to treat postmenopausal women diagnosed with hormone-receptor-positive, HER2-positive metastatic breast cancer.
Doctors can choose to use Tykerb to treat other stages of breast cancer whether or not that particular use is officially approved by the FDA.
In this section you can learn more about: